Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Proximity Network Assay: driving the future of high-resolution protein interactomics in 3D for precision medicine, drug discovery, and molecular diagnostics

Project description

Mapping the hidden networks of life

Proteins perform critical tasks and are necessary for nearly all biological processes. Diseases such as cancer may develop when they do not work properly. For precision medicine to advance, it is essential to comprehend how proteins interact inside cells. In order to tackle this, the EIC-funded PNA project has created a DNA-based method that maps protein interactions with remarkable 30-nanometer resolution. It can analyse more than 150 protein markers without the use of complex microscopy, enabling faster, more affordable, and scalable protein mapping. This has the potential to transform drug development, diagnostics, and customised healthcare.

Objective

Pixelgen Technologies, a deep-tech Swedish life sciences company, pioneers innovation in spatial proteomics and interactomics, critical for precision medicine, cancer research, and drug discovery. Building on the success of its Molecular Pixelation (MPX) technology, Pixelgen introduces the Proximity Network Assay (PNA), enabling high-resolution, high-throughput protein mapping. The PNA technology addresses current limitations in spatial proteomics and interactomics:low resolution, scalability challenges, and high costs of traditional microscopy-dependent methods.
PNA technology employs a unique DNA-based approach, achieving an unprecedented 30 nm resolution and multiplexing over 150 targeted protein markers in a single assay. Diseases are caused by aberrant cell function. These functions are executed by protein interactome dynamics, currently not studied at scale. PNA will allow researchers to assay intricate protein interactions at both cellular and subcellular levels (including cell-to-cell interactions and FFPE tissues), unlocking insights into immune responses, drug mechanisms, and disease pathology. PNA eliminates the need for expensive and low-content optical imaging systems, providing a cost-effective and accessible solution for academic and industrial applications.
PNA is currently at TRL6, with proof-of-concept data generated for key use cases. The EIC Accelerator project aims to develop PNA to TRL9 by advancing reagent development, creating optimised sample preparation protocols for FFPE tissues and cell-to-cell interaction studies, and enhancing data processing software for seamless integration with multi-omics platforms.
PNA technology will redefine spatial proteomics, enabling groundbreaking research and fostering Europe’s leadership in the biotechnology sector. The project aligns with the EU’s priorities in healthcare and digital transformation, contributing to the European Health Union’s goals of advancing diagnostics and personalised treatment.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2025-ACCELERATOR-02

See all projects funded under this call

Coordinator

Pixelgen Technologies AB
Net EU contribution
€ 2 499 999,00
Address
Hagaplan 4
113 68 Stockholm
Sweden
SME
Yes
Region
Östra Sverige Stockholm Stockholms län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data